Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline to Witness Remarkable Growth due to Adoption of Advanced Regulatory Approaches by the Drug Developers | Top Key players are Prothena Corporation plc, Asceneuron SA, Prana Biotechnology, Biogen, Al

PSP is identified as a rare brain disorder, which affects the control of eye movement and walking. Individuals with PSP also face difficulty in swallowing, speaking, and controlling other voluntary movements. This disease slowly progresses and damages nuclei of neurons in brain. Neuropsychological testing, magnetic resonance imaging (MRI), and eye movement physical examinations are used to diagnose PSP.

Download the sample report at: https://www.pharmaproff.com/request-sample/1230

As per the current scenario, there is no marketed products available for primary treatment of PSP. Some symptomatic treatments available for PSP include physiotherapy, change in diet plan, speech and language therapy, occupational therapy, and intake of anti-depressants.
According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage of this is that the entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for PSP through intravenous route has shown promising results in clinical studies.

Browse Detailed Report at: https://www.pharmaproff.com/report/psp-pipeline-analysis

Companies that are involved in developing therapeutics for PSP have shown positive clinical results in various phases of drug development. For instance, in October 2018, Biogen Inc. announced positive results of phase II trial of its drug candidate “BIIB092” for the treatment of PSP. The results of the study concluded that BIIB092 was generally well-tolerated among patients.

Since there is no marketed products for PSP, companies are actively seeking designation grants to accelerate the process of development. For instance, in July 2018, Asceneuron SA received Orphan Drug Designation by the United States Food and Drug Administration (USFDA) for its potential therapeutic candidate, ASN120290, for the treatment of PSP.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1230

AbbVie Inc., Déclion Inc., Alectos Therapeutics Inc., Prothena Corporation plc, Asceneuron SA, Prana Biotechnology Limited, Biogen Inc., and AlzProtect S.A.S. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of PSP.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.